Astellas Pharma Inc.
15.06 -0.29 (-1.89%)
- Market Cap
- $27.00B
- Volume
- 11K
- Dividend yield
- 3.29%
- Next earnings date
- Oct 29, 2026
Astellas Pharma Inc. (ALPMY) Stock Price, Analysis & Data
You're seeing the free overview
Create a free account to open financials, options, forecasts and the rest of this ticker.
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →$17,40
15.54% upside
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 15
- Market Cap
- 27B
- Revenue (ttm)
- 2.27T
- Net Income (ttm)
- 365B
- 0.09
- 1.03
- 14.62
- 33.47
- P/B (ttm)
- 2.19
- P/S (ttm)
- 0.01
- Earnings Date
- Oct 29, 2026
- Ask
- 15.11
- Volume
- 10,964
- Avg. Volume (20D)
- 141,438
- Open
- 15.25
- Previous Close
- 15.35
- Day's Range
- 14.98 - 15.25
- 52-Week Range
- 10.03 - 17.35
- Analyst
- n/a
- Price Target
- 17.4 (15.54%)
- Dividends
- $0.50 (3.29%)
- Ex-Dividend Date
- Mar 31, 2026
About Astellas Pharma Inc.
View profile →Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Dec 29, 2009
Employees 14,099
Stock Exchange OTC Markets OTCPK
Ticker Symbol ALPMY
Website https://www.astellas.com